Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 26-50 of 40 citing articles:

Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database
Shangze Li, Runcheng Huang, Yuanyuan Meng, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
A real-world pharmacovigilance study of nusinersen based on the FAERS database
Weiling Guo, Yi Fang, Aiguang Xu, et al.
Research Square (Research Square) (2024)
Open Access
Multidimensional assessment of adverse events of finasteride:a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024
Xiaoling Zhong, Yihan Yang, Sheng Wei, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Post-marketing safety of tralokinumab: a real-world pharmacovigilance study based on the FDA adverse event reporting system
Zeping Yang, Kejing Tang, Jie Chen
Expert Opinion on Drug Safety (2024)
Closed Access
Comprehensive Analysis of Adverse Events Associated with Vortioxetine Using the FDA Adverse Event Reporting System
Liangxia Li, Qianqian Xu, Liangfang Pang, et al.
(2024)
Closed Access
Analysis of tirzepatide in the US FDA adverse event reporting system (FAERS): a focus on overall patient population and sex-specific subgroups
Yingyong Ou, Zhiwei Cui, Siyu Lou, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Safety concerns of aztreonam: a real-world disproportionality analysis based on FDA adverse event reporting system
Lili Cai, Hong Zhou, Namei Wu, et al.
Expert Opinion on Drug Safety (2024)
Closed Access
Postmarketing Safety Surveillance of Topiramate: A Signal Detection and Analysis Study Based on the FDA Adverse Event Reporting System Database
Kai Lin, Mengjiao He, Zuoqi Ding
Journal of Evidence-Based Medicine (2024) Vol. 17, Iss. 4, pp. 795-807
Closed Access
A real‑world pharmacovigilance study of raloxifene based on the FDA adverse event reporting system (FAERS)
Hao Liu, Wei Yan, Di Luo, et al.
Expert Opinion on Drug Safety (2024)
Closed Access
Adverse drug events associated with metreleptin administration: a real-world pharmacovigilance study from 2014 to 2024 using the FAERS database
Junhao He, Xuan Luo, Jie Liu, et al.
Expert Opinion on Drug Safety (2024)
Closed Access
A real-world pharmacovigilance analysis for agalsidase beta: findings from the FDA adverse event reporting database
Wen-Long Xie, Hou‐Hong Li, Di Li, et al.
Expert Opinion on Drug Safety (2024), pp. 1-12
Closed Access
Medication -Induced Rhabdomyolysis: A Disproportionality Analysis of the FAERS Data
Liuyin Jin, Yixia Zhou, Guoming Xie, et al.
(2024)
Closed Access
Assessment of safety profile of ivabradine in real-world scenario using FDA adverse event reporting system database
Fajun Li, Xin Su, Fuliang Cai
Expert Opinion on Drug Safety (2024), pp. 1-7
Closed Access
Adverse events associated with Tezepelumab: a safety analysis of clinical trials and a pharmacovigilance system
Zhenyu Mao, Yuchen Huang, Xiaoyan Zhu, et al.
Expert Opinion on Drug Safety (2024), pp. 1-10
Open Access
Which fluoroquinolone is safer when combined with bedaquiline for tuberculosis treatment: evidence from FDA Adverse Event Reporting System database from 2013 to 2024
Sheng Wei, Changping He, Xiangping Xie, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Previous Page - Page 2

Scroll to top